Neurocrine Biosciences, Inc. NBIX
164.63 USD +4.87 (+3.05%)
At closeNov 6, 2026, 4:27 PM EST
164.63 0.00 0.00%
After hours · Nov 6, 4:27 PM ET
158.66 Day range 165.86
123.10 52-week range 185.50
- YTD
- +16.08%
- 1 year
- +6.35%
News
benzinga.com Neurocrine Biosciences Releases Findings From New Survey Showing Adults With Tardive Dyskinesia Reported Fewer Disruptions To Work, School After Starting Treatment With INGREZZA Capsules Survey reveals work or school disruptions among adults with tardive dyskinesia declined from 57% before treatment to 21% after starting INGREZZA, with average missed days per month decreasing from…
prnewswire.com Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules Survey reveals work or school disruptions among adults with tardive dyskinesia declined from 57% before treatment to 21% after starting INGREZZA, with average missed days per month decreasing from…
defenseworld.net Neurocrine Biosciences, Inc. $NBIX Shares Newly Bought by Factory Mutual Insurance Co. Factory Mutual Insurance Co. acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) during the undefined quarter, according to the company in its most recent 13F filing with…
seekingalpha.com Neurocrine Biosciences: Breaking Down A Solid Quarter Neurocrine Biosciences delivered robust Q3 results Monday after the bell, with EPS of $3.29 and revenue up 41% to $1.12 billion. INGREZZA remains NBIX's primary growth driver, posting 17%…
benzinga.com Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $224 Guggenheim analyst Delma Caiati maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $207 to $224.
seekingalpha.com Neurocrine Biosciences: 3 Growth Drivers And An Attractive Valuation Neurocrine Biosciences is in an attractive growth phase, driven by strong INGREZZA sales and rapid expansion of CRENESSITY and VYKAT XR. Q3 2026 revenue grew 41% year-over-year to $1.123 billion,…
seekingalpha.com Neurocrine Biosciences: Up 15% After Q3, And The Research Engine Is Still Almost Free Neurocrine Biosciences is reiterated as a buy with a new fair value of $195.80, 19% above the recent price. The investment thesis centers on NBIX's underappreciated early research engine, now valued…
defenseworld.net Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Breaks Above Two Hundred Day Moving Average on Insider Selling Neurocrine Biosciences, Inc. (NASDAQ: NBIX - Get Free Report)'s share price passed above its 200-day moving average during trading on Tuesday after an insider bought additional shares in the company.…
prnewswire.com Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress SAN DIEGO, Nov. 3, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its participation in the 2026 Neuroscience Education Institute (NEI) Fall Congress, taking place…
benzinga.com Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $185 Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $183 to $185.
benzinga.com Nasdaq 100 Gets a Lift As Nvidia Overtakes Apple: Stock Market Today Apple's memory-cost margin warning hands Nvidia the top market value as chipmakers rebound. Here's what's happening in the stock market today.
zacks.com NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales View Neurocrine Biosciences beats Q3 earnings and revenue estimates as strong Ingrezza demand, Crenessity growth and higher 2026 sales guidance drive momentum.
benzinga.com Fabrinet, EverQuote, Lattice Semiconductor, Fiserv And Other Big Stocks Moving Higher On Tuesday U.S. stocks mixed as Dow fell 200 points; Fabrinet surged 13.7% on strong results, guidance and buyback, while several small caps rallied.- benzinga.com RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $190 RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $187 to $190.
- benzinga.com Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $220 Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $210 to $220.
benzinga.com Piper Sandler Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $215 Piper Sandler analyst David Amsellem maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $210 to $215.
marketbeat.com Neurocrine Biosciences Q3 Earnings Call Highlights Neurocrine Biosciences NASDAQ: NBIX reported record third-quarter net product sales exceeding $1.1 billion and record operating profitability, supported by growth across its three marketed medicines:…
seekingalpha.com Neurocrine Biosciences, Inc. (NBIX) Q3 2026 Earnings Call Transcript Neurocrine Biosciences, Inc. (NBIX) Q3 2026 Earnings Call Transcript
zacks.com Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates Neurocrine Biosciences (NBIX) came out with quarterly earnings of $3.29 per share, beating the Zacks Consensus Estimate of $2.54 per share. This compares to earnings of $2.04 per share a year ago.
zacks.com Neurocrine (NBIX) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
benzinga.com Neurocrine Biosciences Raises FY 2026 INGREZZA Net Product Sales Guidance from $2.825B-$2.875B to $2.900B-$2.925B Neurocrine Biosciences (NASDAQ:NBIX) Raises FY 2026 INGREZZA Net Product Sales Guidance from $2.825B-$2.875B to $2.900B-$2.925B
prnewswire.com Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results Total Third-Quarter 2026 Revenue Grew 41% Year-Over-Year to $1.1 Billion INGREZZA® (valbenazine) 2026 Net Sales Guidance Raised to $2.9 to $2.925 Billion SAN DIEGO, Nov. 2, 2026 /PRNewswire/ --…
benzinga.com Neurocrine Biosciences Q3 Adj. EPS $3.29 Beats $1.91 Estimate, Sales $1.119B Beat $1.043B Estimate Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $3.29 per share which beat the analyst consensus estimate of $1.91 by 72.25 percent. This is a 51.61 percent increase over earnings…
zacks.com Here's Why Neurocrine Biosciences (NBIX) is a Strong Value Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
benzinga.com Apple, Palantir On Deck Monday As AI Demand, iPhone Growth Face Test Apple headlines Monday’s reports, with investors looking for continued iPhone momentum and evidence that its artificial-intelligence push can support the company’s next leg of growth. Marriott…- benzinga.com Neurocrine Biosciences Identifies Clinically Meaningful Health Improvement Threshold For INGREZZA In Tardive Dyskinesia Patients New analysis establishes a 6-point increase on the EQ Visual Analogue Scale as a threshold for clinically meaningful change in overall health ratings in patients with tardive dyskinesia treated with
- benzinga.com Neurocrine Biosciences Announces Publication Of Expert Perspectives Highlighting Hyperphagia In Prader-Willi Syndrome As Neurobiologically Driven Condition Expert perspectives highlight the interaction of hypothalamic dysfunction, biological, behavioral, and environmental factors in shaping the challenges of hyperphagia in Prader-Willi syndrome for…
benzinga.com Neurocrine Biosciences Starts Phase 2 Clinical Trial Of NBI-1117567 To Treat Adults With Mild To Moderate Alzheimer's Disease Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1117567 (NBI-'567) in adults with mild to moderate Alzheimer's…
benzinga.com Neurocrine Biosciences To Report Impact Of Classical Congenital Adrenal Hyperplasia At Endocrine Nurses Society Annual Symposium 2026 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new real-world data demonstrating how the clinical and day-to-day impact of classic congenital adrenal hyperplasia can vary among…- benzinga.com Needham Reiterates Buy on Neurocrine Biosciences, Maintains $204 Price Target Needham analyst Ami Fadia reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and maintains $204 price target.
- benzinga.com BMO Capital Maintains Market Perform on Neurocrine Biosciences, Lowers Price Target to $150 BMO Capital analyst Evan Seigerman maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Market Perform and lowers the price target from $164 to $150.
- benzinga.com Guggenheim Assumes Neurocrine Biosciences at Buy, Announces Price Target of $207 Guggenheim analyst Delma Caiati assumes Neurocrine Biosciences (NASDAQ:NBIX) with a Buy rating and announces Price Target of $207.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Jim Cramer Says Buy Uber, Calls Rockwell Automation 'One Ugly Chart' but a 'Great Long-Term Situation' Jim Cramer recommended buying Uber, Tanger, Rockwell Automation, Amcor, and Neurocrine Biosciences. Uber and Zipline announced a partnership for autonomous delivery. Tanger and Amcor both reported…
benzinga.com Tom Lee's Small-Cap Granny Shots ETF Reloads: First Solar, Zoom Among 10 New Buys Tom Lee's GRNJ added First Solar, Zoom and eight other stocks in its latest rebalance as assets under management climbed to $476 million.
benzinga.com Earnings Scheduled For May 5, 2026 
benzinga.com Arista Networks To Rally Around 43%? Here Are 10 Top Analyst Forecasts For Tuesday Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, including upgrades and downgrades, on our analyst ratings page.
benzinga.com Neurocrine Buys Soleno To Tap High-Growth Rare Disease Market Neurocrine (NBIX) to acquire Soleno Therapeutics (SLNO) for $2.9B to expand its rare disease portfolio. Get the deal details here.
benzinga.com McDonald's To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Thursday - benzinga.com Earnings Scheduled For February 11, 2026
benzinga.com Zoom To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Tuesday 
benzinga.com S&P 500 Tops 6,900 Ahead Fed Rate Move, Gold Reclaims $4,000: What's Moving Markets Wednesday? A powerful surge in AI-related stocks — led by a 9% advance in NVIDIA Corp. (NASDAQ:NVDA) over the past two sessions — propelled the S&P 500 above the 6,900 mark and lifted the Nasdaq 100 to 26,100…
benzinga.com Earnings Scheduled For October 28, 2025 - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session. The market value of their outstanding shares is at $87.2 million.
- benzinga.com Earnings Scheduled For July 30, 2025
benzinga.com FARO Technologies, Celanese, Avient, Aramark And Other Big Stocks Moving Higher On Tuesday 
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session - benzinga.com Earnings Scheduled For May 5, 2025
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session